Roth MKM raised the firm’s price target on Globus Medical (GMED) to $115 from $100 and keeps a Buy rating on the shares. The stock’s 2024 outperformance justified the firm’s “Top Pick” call for this year as the company’s salesforce retention was better than what the Street was anticipating, the analyst tells investors in a research note. The firm sees 2025 for the company having “continued outperformance”, driven by topline acceleration and margin acceleration, as merger-related synergies kick in.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $91 from $87 at BTIG
- Globus Medical price target raised to $92 from $85 at Canaccord
- Globus Medical assumed at Overweight from Equal Weight at Morgan Stanley
- Globus Medical launches ExcelsiusHub navigation system
- Globus Medical price target raised to $83 from $74 at Morgan Stanley